Results 231 to 240 of about 826,071 (315)

Arg1 and Tgfb1 Identify a Partially Shared Macrophage Polarization Program in Postinfarction Cardiac Repair: A Single-Cell Transcriptomic Analysis

International Journal of Genomics
Baobao Liu, Fuli Liang
doaj   +1 more source

In-stent neoatherosclerosis: a new problem or an opportunity to rethink the treatment of coronary disease? [PDF]

AsiaIntervention
Ussia GP, Cocco N.
europepmc   +1 more source

On Pulmonary and Coronary Diseases…

The Anatolian Journal of Cardiology
openaire   +2 more sources

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

British Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay, Amandine Manon, Hunter Stephens, S. Y. Amy Cheung, Bart de Keizer, Erik T. te Beek   +5 more
wiley   +1 more source

Ectopic adipose tissue in subsistence populations with minimal coronary disease, large left atria, and very low rates of atrial fibrillation. [PDF]

Am J Prev Cardiol
Thompson RC, Trumble BC, Cummings DK, Neunuebel AD, Hooper PL, Wann S, Allam AH, Neunuebel F, Gans BD, King SI, Seabright E, Finch CE, Gatz M, Buetow K, Miyamoto MI, Lombardi GP, Sutherland ML, Sutherland JD, Ward C, Lee MJ, Mahadev A, Rodriguez DE, Michalik DE, Rowan CJ, Cao T, Stieglitz J, Quick CM, Thomas GS, Narula J, Dey D, Gurven M, Kaplan H.   +31 more
europepmc   +1 more source

Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway

British Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to compare how Norwegian healthcare professionals (HCPs) and consumers reported the same adverse event (AE) following immunization with vaccines against COVID‐19 during the COVID‐19 pandemic. Specifically, we aimed to compare the extent to which HCPs and consumers reported information relevant for assessing the causal relationship ...
Tommy Emil Dzus, Johaina Sarrage, Hilde Samdal, François Montastruc, Elena Rocca   +4 more
wiley   +1 more source

Measuring and Targeting Persistent Inflammation in Chronic Coronary Disease. [PDF]

JACC Adv
Frangogiannis NG.
europepmc   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

An Ounce of Prevention for a Pound of Cure?: Lipid-Lowering Therapy for Premature Coronary Disease. [PDF]

JACC Adv
Khurshid S, Kany S.
europepmc   +1 more source

Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon, Wendy Wang, Faye L. Norby, Rob F. Walker, Shalini Kulasingam, Lisa S. Chow, Joel F. Farley, Pamela L. Lutsey   +7 more
wiley   +1 more source